← FDA DRUG APPROVALS

FDA BLA · BLA761404

STOBOCLO

denosumab-bmwo

Sponsor: CELLTRION INC

APPLICATION
BLA761404
TYPE
BLA
ORIGINAL APPROVAL
2025-02-28
LATEST ACTION
2025-10-29
ROUTE
SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

OSENVELTPrescription
DENOSUMAB-BMWO 120MG/1.7ML(70MG/ML) · INJECTABLE · INJECTION
STOBOCLOPrescription
DENOSUMAB-BMWO 60MG/ML · INJECTABLE · INJECTION

Approval history

2025-10-29Efficacy · Original · standardLetterAP
2025-09-10Labeling · Supplement 3 · standardLetterAP
2025-02-28UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →